Advanced search

Authors whose works are in public domain in at least one jurisdiction

List of works by Kenneth C. Anderson

1-50 of 669 results

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

scientific article (publication date: 16 September 2011)

A phase 2 study of bortezomib in relapsed, refractory myeloma

scientific article

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

scientific article published in June 2005

Multiple Myeloma

scientific article published in March 2011

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

scientific article

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

scientific article

Initial genome sequencing and analysis of multiple myeloma

scientific article

High-throughput oncogene mutation profiling in human cancer

article

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets

scientific article published on August 2007

Lenalidomide after stem-cell transplantation for multiple myeloma

scientific article

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer

scientific article

NF-kappa B as a therapeutic target in multiple myeloma

scientific article

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

scientific article published on 2 June 2015

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

scientific article

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

scientific article published on 3 August 2015

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

scientific article

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

scientific article published on 03 February 2011

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

scientific article published on January 2014

Multiple myeloma

scientific article published in The Lancet

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

scientific article

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

scientific article published on August 2016

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

scientific article

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

scientific article published in June 2002

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

scientific article

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

scientific article published on 7 November 2002

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

scientific article (publication date: 19 August 2003)

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma

scientific article published on September 2014

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

scientific article

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

scientific article published on 26 September 2002

Advances in biology of multiple myeloma: clinical applications

scientific article published on 15 April 2004

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

scientific article published on 26 December 2003

BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

scientific article published on April 2013

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

scientific article published in March 2004

Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy

scientific article published on October 27, 2011

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

scientific article published on 19 January 2012

Proteasome inhibition as a novel therapeutic target in human cancer.

scientific article

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

scientific article published on 13 July 2006

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

scientific article published on 05 May 2009

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

scientific article

The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis

scientific article published in April 2007

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

scientific article published on 23 January 2006

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients

article

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

scientific article published in August 2002

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

scientific article published on 17 January 2006

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

scientific article published on 28 September 2007

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

scientific article published on April 2017

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

scientific article published on 09 August 2007

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

scientific article published on 05 June 2006

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

scientific article

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma

scientific article published on 21 May 2007